Your browser doesn't support javascript.
loading
Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data.
Stöber, Alisa; Lutter, Johanna I; Schwarzkopf, Larissa; Kirsch, Florian; Schramm, Anja; Vogelmeier, Claus F; Leidl, Reiner.
Afiliação
  • Stöber A; Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, Neuherberg, Germany.
  • Lutter JI; Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University Munich (LMU), Munich, Germany.
  • Schwarzkopf L; Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, Neuherberg, Germany.
  • Kirsch F; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Schramm A; Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, Neuherberg, Germany.
  • Vogelmeier CF; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Leidl R; Institute fuer Therapieforschung (IFT), Working Group Therapy and Health Services Research, Munich, Germany.
Int J Chron Obstruct Pulmon Dis ; 16: 2637-2651, 2021.
Article em En | MEDLINE | ID: mdl-34588773
PURPOSE: Real-world evidence on the impact of forced expiratory volume in one second (FEV1) and exacerbations on health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) is sparse especially with regard to GOLD ABCD groups. This study investigates how changes in FEV1 and exacerbations affect generic and disease-specific HRQoL in COPD patients over one year. METHODS: Using German claims data and survey data, we classified 3016 COPD patients and analyzed their health status by GOLD groups AB and CD. HRQoL was measured with the disease-specific COPD assessment test (CAT) and the visual analog scale (VAS) from the generic Euro-Qol 5D-5L. We applied change score models to assess associations between changes in FEV1 (≥100 mL decrease/no change/≥100 mL increase) or the development of severe exacerbations with change in HRQoL. RESULTS: FEV1 decrease was associated with a significant but not minimal important difference (MID) deterioration in disease-specific HRQoL (mean change [95% CI]: CAT +0.74 [0.15 to 1.33]), while no significant change was observed in the generic VAS. Experiencing at least one severe exacerbation also had a significant impact on CAT deterioration (+1.58 [0.52 to 2.64]), but again not on VAS. Here, GOLD groups AB showed not only a statistically but also a clinically relevant MID deterioration in CAT (+2.1 [0.88 to 3.32]). These particular patient groups were further characterized by a higher probability of being male, having a higher mMRC and Charlson index, and a lower probability of having higher FEV1 or BMI values. CONCLUSION: FEV1 decline and the occurrence of ≥1 severe exacerbation are significantly associated with overall deterioration in disease-specific HRQoL. Preventing severe exacerbations particularly in patients without previous severe exacerbations (ABCD groups A and B) may help to stabilize the key patient-reported outcome HRQoL.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans / Male Idioma: En Revista: Int J Chron Obstruct Pulmon Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans / Male Idioma: En Revista: Int J Chron Obstruct Pulmon Dis Ano de publicação: 2021 Tipo de documento: Article